| Literature DB >> 34911526 |
Mengjun Shen1, Ying Zhou2, Weiqing Gu2, Chengsheng Yin2, Yin Wang3, Yuan Zhang4.
Abstract
OBJECTIVE: To explore the significance of neck ultrasound (NUS) combined with contrast-enhanced ultrasound (CEUS) in the diagnosis of sarcoidosis.Entities:
Keywords: CEUS; Cervical lymphadenopathy; Sarcoidosis; Tuberculosis; Ultrasound
Mesh:
Year: 2021 PMID: 34911526 PMCID: PMC8672511 DOI: 10.1186/s12890-021-01769-z
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Elasticity scoring system
| Score | Performance |
|---|---|
| 0 | The focus area is mainly cystic components, showing red, blue and green alternately |
| 1 | The lesion area and the surrounding tissue are uniformly green |
| 2 | The focus area is mainly green (green area > 90%) |
| 3 | The focus area is messy blue-green or mainly blue (blue area is 50–90%) |
| 4 | The lesion area is almost blue covered (blue area > 90%) |
Demographic information of subjects recruited
| Category | Sarcoidosis group | Control subjects | ||
|---|---|---|---|---|
| Tuberculosis group | Malignancy group | Inflammatory group | ||
| Total subjects, n | 20 | 23 | 22 | 23 |
| Age, years | 47.1 ± 12.7 | 44.1 ± 15.0 | 65.6 ± 10.0 | 57.5 ± 6.2 |
| Gender | ||||
| Male | 9 (45.0%) | 9 (39.1%) | 17 (77.3%) | 13 (56.5%) |
| Female | 11 (55.0%) | 14 (60.9%) | 5 (22.7%) | 10 (43.5%) |
| CXR stage 0/I/II/III/IV § | 0/4/18/0/0 | N/A | N/A | N/A |
| Biopsy (cases/needles) | ||||
| NUS FNA | 20/20 | 23/23 | 22/22 | 23/23 |
| NUS CNB | 17/20 | 23/23 | 22/22 | 20/23 |
| EBUS-TBNA/EBB/TBLB | 19/19 | 18/18 | 20/20 | 20/20 |
| Surgical biopsy | 3/3 | 0/0 | 2/2 | 0/0 |
CXR = chest X-ray; N/A = not applicable; CXR stage: 0 = no adenopathy, no lung infiltrates; stage I = hilar & mediastinal adenopathy only; stage II = hilar & mediastinal adenopathy plus lung infiltrates; stage III = lung infiltrates only; stage IV = pulmonary fibrosis. EBUS-TBNA = endobronchialultrasound-guidedtransbronchialneedleaspiration, EBB = Endobronchialbiopsy; TBLB = transbronchiallungbiopsy
Characteristics of patients with sarcoidosis and cervical lymphadenopathy
| No | Size of cervical LNa | Side of cervical LN | Thoracic LN | FNA result | CNB result |
|---|---|---|---|---|---|
| 1 | 18 | Right | Yes | Adequate but nondiagnostic | Diagnostic |
| 2 | 9 | Bilateral | Yes | Adequate but nondiagnostic | Diagnostic |
| 3 | 14 | Bilateral | Yes | Adequate but nondiagnostic | Diagnostic |
| 4 | 18 | Bilateral | Yes | Adequate but nondiagnostic | Diagnostic |
| 5 | 13 | Bilateral | Yes | Adequate but nondiagnostic | Diagnostic |
| 6 | 8 | Bilateral | Yes | Adequate but nondiagnostic | Diagnostic |
| 7 | 8 | Bilateral | Yes | Adequate but nondiagnostic | Diagnostic |
| 8 | 11 | Bilateral | Yes | Adequate but nondiagnostic | Diagnostic |
| 9# | 7 | Right | Yes | Adequate but nondiagnostic | Not done |
| 10 | 10 | Bilateral | Yes | Adequate but nondiagnostic | Diagnostic |
| 11 | 13 | Bilateral | Yes | Diagnostic | Diagnostic |
| 12# | 7 | Bilateral | Yes | Adequate but nondiagnostic | Not done |
| 13 | 11 | Bilateral | Yes | Adequate but nondiagnostic | Diagnostic |
| 14 | 8 | Bilateral | Yes | Adequate but nondiagnostic | Diagnostic |
| 15 | 9 | Bilateral | Yes | Adequate but nondiagnostic | Diagnostic |
| 16 | 12 | Bilateral | Yes | Adequate but nondiagnostic | Diagnostic |
| 17# | 15 | Bilateral | Yes | Adequate but nondiagnostic | Not done |
| 18 | 8 | Bilateral | Yes | Adequate but nondiagnostic | Diagnostic |
| 19 | 17 | Bilateral | Yes | Adequate but nondiagnostic | Diagnostic |
| 20 | 14 | Bilateral | Yes | Adequate but nondiagnostic | Diagnostic |
aDiameter of largest lymph node on ultrasound was in millimeter. # Case 9 was dianosed by EBUS-TBNA and EBB. Case 12 and 17 were underwent mediastinal biopsy. CNB, core needle biopsy; FNA, fine-needle aspiration; LN, lymph node
Neck ultrasound (NUS) features in sarcoidosis versus non-sarcoidosis groups
| Category | Sarcoidosis group | Control subjects | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis Group | Malignancy Group | Inflammatory Group | Total | ||||||
| Symmetry | |||||||||
| Bilateral | 18 (90.0%) | 5 (21.7%) | < 0.001 | 10 (45.5%) | 0.002 | 10 (43.5%) | 0.001 | 25 (36.8%) | < 0.001 |
| Unilateral | 2 (10.0%) | 18 (78.3%) | 12 (54.5%) | 13 (56.5%) | 43 (63.2%) | ||||
| Number | |||||||||
| 1 | 0 (0) | 0 (0) | – | 1 (4.5%) | 1.000 | 5 (21.7%) | 0.082 | 6 (8.8%) | 0.383 |
| > 1 | 20 (100%) | 23 (100%) | 21 (95.5%) | 18 (78.3%) | 62 (91.2%) | ||||
| Longitudinal meridian(mm) | |||||||||
| ≥ 10 | 12 (60.0%) | 19 (82.6%) | 0.099 | 19 (86.4%) | 0.052 | 3 (13.0%) | 0.001 | 41 (60.3%) | 0.981 |
| < 10 | 8 (40.0%) | 4 (17.4%) | 3 (13.6%) | 20 (87.0%) | 27 (39.7%) | ||||
| Aspect ratio | |||||||||
| < 2 | 14 (70.0%) | 19 (82.6%) | 0.539 | 20 (90.9%) | 0.361 | 13 (56.5%) | 0.362 | 52 (76.5%) | 0.557 |
| ≥ 2 | 6 (30.0%) | 4 (17.4%) | 2 (9.1%) | 10 (43.5%) | 16 (23.5%) | ||||
| Lymphatic hilum | |||||||||
| Presence | 0 (0) | 1 (4.3%) | 1.000 | 0 (0) | – | 16 (69.6%) | < 0.001 | 17 (25.0%) | 0.030 |
| Absence | 20 (100%) | 22 (95.7%) | 22 (100%) | 7 (30.4%) | 51 (75.0%) | ||||
| Echo | |||||||||
| Hyperechoic | 0 (0) | 1 (4.3%) | 1.000 | 0 (0) | – | 0 (0) | – | 1 (1.5%) | 0.513 |
| Hypoechoic | 20 (100%) | 22 (95.7%) | 22 (100%) | 23 (100%) | 67 (98.5%) | ||||
| Homogeneity | |||||||||
| Uniform | 15 (75.0%) | 3 (13.0%) | < 0.001 | 12 (54.5%) | 0.167 | 15 (65.2%) | 0.486 | 30 (44.1%) | 0.015 |
| Non-uniform | 5 (25.0%) | 20 (87.0%) | 10 (45.5%) | 8 (34.8%) | 38 (55.9%) | ||||
| Border | |||||||||
| Clear | 20 (100%) | 13 (56.5%) | 0.003 | 21 (95.5%) | 1.000 | 23 (100%) | – | 57 (83.8%) | 0.124 |
| Unclear | 0 (0) | 10 (43.5%) | 1 (4.5%) | 0 (0) | 11 (16.2%) | ||||
| Calcification | |||||||||
| Presence | 0 (0) | 4 (17.4%) | 0.152 | 0 (0) | – | 0 (0) | – | 4 (5.9%) | 0.617 |
| Absence | 20 (100%) | 19 (82.6%) | 22 (100%) | 23 (100%) | 64 (94.1%) | ||||
| Fusion | |||||||||
| Presence | 0 (0) | 9 (39.1%) | 0.006 | 0 (0) | – | 0 (0) | – | 9 (13.2%) | 0.194 |
| Absence | 20 (100%) | 14 (60.9%) | 22 (100%) | 23 (100%) | 59 (86.8%) | ||||
| CDFI pattern | |||||||||
| Portal | 3 (15.0%) | 2 (8.7%) | 0.027 | 0 (0) | 0.001 | 17 (73.9%) | < 0.001 | 19 (27.9%) | < 0.001 |
| Dendritic | 9 (45.0%) | 2 (8.7%) | 1 (4.5%) | 0 (0) | 3 (4.4%) | ||||
| Annular | 1 (5.0%) | 4 (17.4%) | 0 (0) | 0 (0) | 4 (5.9%) | ||||
| Other | 7 (35.0%) | 15 (65.2%) | 21 (95.5%) | 6 (26.1%) | 42 (61.8%) | ||||
| Elasticity score | |||||||||
| ≥ 3 | 16 (80.0%) | 14 (60.9%) | 0.173 | 16 (72.7%) | 0.849 | 6 (26.1%) | < 0.001 | 36 (52.9%) | 0.030 |
| < 3 | 4 (20.0%) | 9 (39.1%) | 6 (27.3%) | 17 (73.9%) | 32 (47.1%) | ||||
CDFI: Color Doppler Flow Imaging; 1Sarcoidosis versus Tuberculosis Group; 2Sarcoidosis versus Malignancy Group; 3Sarcoidosis versus Inflammatory Group; 4Sarcoidosis versus Non-sarcoidosis groups
Contrast-enhanced ultrasound (CEUS) features in sarcoidosis versus non-sarcoidosis groups
| Category | Sarcoidosis group | Control subjects | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis group | Malignancy group | Inflammatory group | Total | ||||||
| Enhanced mode | |||||||||
| Centripetal | 0 (0) | 13 (56.5%) | < 0.001 | 16 (72.7%) | < 0.001 | 4 (17.4%) | < 0.001 | 33 (48.5%) | < 0.001 |
| Centrifugal | 3 (15.0%) | 6 (26.1%) | 1 (4.5%) | 19 (82.6%) | 26 (38.2%) | ||||
| Polycentric | 17 (85.0%) | 2 (8.7%) | 3 (13.6%) | 0 (0) | 5 (7.4%) | ||||
| Annular | 0 (0) | 2 (8.7%) | 2 (9.1%) | 0 (0) | 4 (5.9%) | ||||
| Enhanced degree | |||||||||
| Low/equal | 2 (10.0%) | 2 (8.7%) | 0.950 | 0 (0) | 0.647 | 0 (0) | 0.210 | 2 (2.9%) | 0.471 |
| High | 18 (90.0%) | 21 (91.3%) | 22 (100%) | 23 (100%) | 66 (97.1%) | ||||
| Homogeneity | |||||||||
| Uniform | 20 (100%) | 4 (17.4%) | < 0.001 | 10 (45.5%) | < 0.001 | 23 (100%) | – | 37 (54.4%) | < 0.001 |
| Non-uniform | 0 (0) | 19 (82.6%) | 12 (54.5%) | 0 (0) | 31 (45.6%) | ||||
| Necrosis | |||||||||
| Presence | 0 (0) | 19 (82.6%) | < 0.001 | 12 (54.5%) | < 0.001 | 0 (0) | – | 31 (45.6%) | < 0.001 |
| Absence | 20 (100%) | 4 (17.4%) | 10 (45.5%) | 23 (100%) | 37 (54.4%) | ||||
| Arrival time (s) | 10.4 ± 2.6 | 11.3 ± 3.1 | 13.3 ± 3.6 | 11.4 ± 3.0 | |||||
| Peak time (s) | 15.5 ± 3.7 | 17.8 ± 3.9 | 21.1 ± 5.1 | 17.7 ± 3.7 | |||||
| Wash-out time (s) | 22.3 ± 4.5 | 25.9 ± 4.0 | 28.4 ± 6.2 | 27.1 ± 3.2 | |||||
1Sarcoidosis versus Tuberculosis Group; 2Sarcoidosis versus Malignancy Group; 3Sarcoidosis versus Inflammatory Group; 4Sarcoidosis versus Non-sarcoidosis groups
Fig. 1A NUS showed right supraclavicular lymphadenopathy, and the target lymph node was hypoechoic, uniform, no lymph hilum, clear border and no fusion. B CEUS showed that the target lymph node showed uniform and high enhancement and there was no non-enhanced area at the peak. C Pathological specimens obtained by ultrasound-guided percutaneous biopsy showed granuloma. (Case1, a 34-year-old male). D NUS showed right supraclavicular lymph node was enlarged, and the target lymph node was hypoechoic, non-uniform, no lymph hilum, clear border and no fusion. E CEUS showed that the target lymph node showed non-uniform and high enhancement, and there were large irregular areas without enhancement at the peak. F Pathological specimens obtained by ultrasound-guided percutaneous biopsy showed necrotizing granuloma. (Case2, a 22-year-old male). G NUS showed right supraclavicular lymph node was enlarged, and the target lymph node was hypoechoic, uniform, no lymphatic hilum, clear border and no fusion. H CEUS showed that the target lymph node showed uniform and equal enhancement, and there was no non-enhanced area at the peak. I Pathological specimens obtained by ultrasound-guided percutaneous biopsy showed granulomatous lesions, no necrosis, acid-fast found a small number of positive bacilli, considering the possibility of tuberculous lesions. (Case3, a 49-year-old female). J NUS showed right supraclavicular lymph node was enlarged, and the target lymph node was hypoechoic, uniform, no lymphatic hilum, clear border and no fusion. K CEUS showed that the target lymph node showed uniform and high enhancement, and there was no non-enhanced area at the peak. L Pathological specimens obtained by ultrasound-guided percutaneous biopsy showed metastatic non-small cell carcinoma, tending to adenocarcinoma. (Case4, a 65-year-old male). M NUS showed right supraclavicular lymph node was enlarged, and the target lymph node was hypoechoic, uniform, no lymphatic hilum, clear border and no fusion. N CEUS showed that the target lymph node showed non-uniform and high enhancement, and there were small irregular non-enhanced areas at the peak. O Pathological specimens obtained by ultrasound-guided percutaneous biopsy showed metastatic small cell carcinoma. (Case5, a 78-year-old male). P NUS showed right supraclavicular lymph node was enlarged, and the target lymph node was hypoechoic, non-uniform, lymphatic hilum, clear border and no fusion. Q CEUS showed that the target lymph node showed uniform and high enhancement, and there was no non-enhanced area at the peak. R Pathological specimens obtained by ultrasound-guided percutaneous biopsy showed lymphoid tissue hyperplasia (Case6, a 60-year-old male). Hematoxylin–eosin stain was used for histopathology and magnification × 100
Fig. 2A CESU manifestation of sarcoidosis is that the enhancement pattern is polycentric. B The metastatic lymph node of lung cancer is centripetal
Fig. 3A 25 characteristics from NUS and CEUS were considered for diagnosis analysis. B, C Seven most significant characteristics were entered into the two classification analysis model. D The percentage correction of prediction was 90%